F
Fabrice Barlesi
Researcher at Aix-Marseille University
Publications - 666
Citations - 36214
Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.
Papers
More filters
Journal ArticleDOI
Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology
Cesare Gridelli,Paul Baas,Fabrice Barlesi,Fortunato Ciardiello,Lucio Crinò,Enriqueta Felip,Shirish M. Gadgeel,Vassiliki A. Papadimitrakopoulou,Luis Paz-Ares,David Planchard,Maurice Pérol,Nasser H. Hanna,Assunta Sgambato,Francesca Casaluce,Filippo de Marinis +14 more
TL;DR: The second‐line algorithm treatment of NSCLC becomes very intricate and the selection of proper patients with one of the new available therapeutic options is of paramount importance to personalize and optimize the treatment.
Journal ArticleDOI
Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay.
Simon Heeke,Jonathan Benzaquen,Audrey Vallee,Maryline Allegra,Julien Mazieres,Julien Fayada,Jaya Rajamani,Michael Lee,Ellen Ordinario,Angelica Tiotiu,Jacques Cadranel,Michel Poudenx,Denis Moro-Sibilot,Fabrice Barlesi,Fabrice Barlesi,Radj Gervais,Juliette Thariat,Virginie Tanga,Jacques Boutros,Marius Ilie,Véronique Hofman,Charles-Hugo Marquette,Marc G. Denis,Paul Hofman +23 more
TL;DR: The prototype Roche ALK/RET RT-PCR assay was able to detect ALK fusion transcripts in the plasma of NSCLC patients at baseline as well as at disease progression with limited sensitivity but high specificity.
Journal ArticleDOI
Anti-TIGIT therapies for solid tumors: a systematic review
TL;DR: In this article , the authors carried out a review of the clinical trial about anti-TIGIT referenced in the PubMed database, finding three published clinical trials on anti-tigIT therapies.
Journal ArticleDOI
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).
Sai-Hong Ignatius Ou,Leena Gandhi,Shirish M. Gadgeel,Fabrice Barlesi,James Chih-Hsin Yang,Luigi De Petris,Dong Wan Kim,Ramaswamy Govindan,Anne-Marie C. Dingemans,Lucio Crinò,Lena Herve,Sanjay Popat,Jin Seok Ahn,Eric Dansin,Ali Zeaiter,Barbara Muller,H. Johannsdottir,Bogdana Balas,Peter N. Morcos,Alice T. Shaw +19 more
TL;DR: Final pooled phase II OS and safety data after a longer duration of follow-up are reported on for alectinib in crizotinib-resistant ALK+ NSCLC.
Journal ArticleDOI
Rationale for the Use of Upfront Whole Brain Irradiation in Patients with Brain Metastases from Breast Cancer
Agnès Tallet,David Azria,Emilie Le Rhun,Fabrice Barlesi,Antoine F. Carpentier,Antony Gonçalves,S. Taillibert,Frédéric Dhermain,Jean-Philippe Spano,Philippe Metellus +9 more
TL;DR: The literature review presented here was conducted in an attempt to collect medical evidence-based data on the use of whole-brain radiotherapy for the treatment of brain metastases from breast cancer.